Abstract:Autoimmune hemolytic anemia (AIHA) is not an uncommon clinical disorder and requires advanced, efficient immunohematological and transfusion support. Many AIHA patients have underlying disorder and therefore, it is incumbent upon the clinician to investigate these patients in detail, as the underlying condition can be of a serious nature such as lymphoproliferative disorder or connective tissue disorder. Despite advances in transfusion medicine, simple immunohematological test such as direct antiglobulin test (DAT) still remains the diagnostic hallmark of AIHA. The sensitive gel technology has enabled the immunohematologist not only to diagnose serologically such patients, but also to characterize red cell bound autoantibodies with regard to their class, subclass and titer in a rapid and simplified way. Detailed characterization of autoantibodies is important, as there is a relationship between in vivo hemolysis and strength of DAT; red cell bound multiple immunoglobulins, immunoglobulin G subclass and titer. Transfusing AIHA patient is a challenge to the immunohematologist as it is encountered with difficulties in ABO grouping and cross matching requiring specialized serological tests such as alloadsorption or autoadsorption. At times, it may be almost impossible to find a fully matched unit to transfuse these patients. However, transfusion should not be withheld in a critically ill patient even in the absence of compatible blood. The "best match" or "least incompatible units" can be transfused to such patients under close supervision without any serious side-effects. All blood banks should have the facilities to perform the necessary investigations required to issue "best match" packed red blood cells in AIHA. Specialized techniques such as elution and adsorption, which at times are helpful in enhancing blood safety in AIHA should be established in all transfusion services.

The Importance for the Correct Intended Use of Autoantibodies in Clinical Context

Autoantibodies - enemies, and/or potential allies?

Summary of the 2011 national autoantibody testing quality control

Quality Control of Autoantibody Detection in China

From autoantibody test results to decision making: Incorporating likelihood ratios within medical practice

The application of autoantibodies detection in the early diagnosis and screening of lung cancer

[Current Practices in the Harmonisation of Autoantibodies Test].

Clinical application of autoimmune neurological diseases related antibodies

Summary of the 2012 national autoantibody testing quality control and comparison with the past 9 years

Issues in autoantibody tests used in the classification criteria for autoimmune rheumatic diseases: the laboratory autoimmunologist's perspective

Application of ANAs Protein Chip in Autoantibodies Proffie Detection

Antigen-free control wells in an ELISA set-up for the determination of autoantibodies against G protein-coupled receptors-a requisite for correct data evaluation

Proteomics-Based Identification of Autoantibodies in the Sera of Healthy Chinese Individuals from Beijing

Laboratory evaluation in rheumatic diseases

Development of Autoantibodies Precedes Clinical Manifestations of Autoimmune Diseases: A Comprehensive Review.

Autoimmune hemolytic anemia: From lab to bedside

Estimating autoantibody signatures to detect autoimmune disease patient subsets

Detection of Posttranslational Modification Autoantibodies Using Peptide Microarray

Main biologics for anti-autoimmune disease:research advances

Autoantibodies as diagnostic and prognostic cancer biomarker: Detection techniques and approaches

Significance of auto-antibodies against islet cells in the diagnosis of type Ⅰdiabetes